drugset / Trial / NCT06250400

Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)

NCT06250400

Phase 4 Unknown 252 enrolled Hangzhou Grand Biologic Pharmaceutical, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to study patients with chronic spontaneous urticaria. The main question it aims to answer is the efficacy and safety of histamine human immunoglobulin (ShuYangMinNing) in the treatment of chronic spontaneous urticaria.

Timeline

Start
2024-03-31
Primary completion
2025-07-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Histamine Human Immunoglobulin Unknown 12 mg Subcutaneous
Background Loratadine Small molecule 10 mg Oral